Light and immunostimulant mediated <i>in situ</i> re-education of tumor-associated macrophages using photosensitizer conjugated mannan nanoparticles for boosting immuno-photodynamic anti-metastasis therapy-Reference-Cited by-同舟云学术

Light and immunostimulant mediated in situ re-education of tumor-associated macrophages using photosensitizer conjugated mannan nanoparticles for boosting immuno-photodynamic anti-metastasis therapy

Published:2023 Issue:1 Volume:11 Page:298-306
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Uthaman Saji¹²^ORCID,Pillarisetti Shameer³^ORCID,Lim Youn-Mook⁴^ORCID,Jeong Jin-Oh⁴,Bardhan Rizia²^ORCID,Huh Kang Moo¹,Park In-Kyu³^ORCID

Affiliation:

1. Department of Polymer Science and Engineering, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea

2. Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 50012, USA

3. Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Gwangju 61469, Republic of Korea

4. Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup-si, Jeollabuk-do, 56212, Republic of Korea

Abstract

Novel co-operative immuno-photodynamic therapy nanoparticles, targeting tumor-associated macrophages, modulating the tumor microenvironment, and preventing tumor metastasis by skewing TAMs to M1-like cells, have been developed.

Funder

National Research Foundation of Korea

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2023/BM/D2BM01508K

Reference29 articles.

1. The future of cancer immunotherapy: microenvironment-targeting combinations

2. Polarization of tumor-associated macrophage phenotype via porous hollow iron nanoparticles for tumor immunotherapy in vivo

3. M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer